# Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

> **NCT07150299** · — · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 20 (estimated)

## Conditions studied

- Hypertrophic Obstructive Cardiomyopathy \(HOCM\)

## Interventions

- **DRUG:** Mavacamten in clinical routine use

## Key facts

- **NCT ID:** NCT07150299
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-05
- **Primary completion:** 2027-05
- **Final completion:** 2027-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07150299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07150299, "Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07150299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*